ESRRA and neoplasm: However, the study conducted in castration-resistant prostate cancer (CRPC), which had higher aggression and frequently occurring bone metastasis, obtained a distinctive conclusion: they found that the overexpression of ERRα significantly increased the progression of CRPC and metastasis in bone, and mechanism investigation revealed that the receptor enhanced the bone remodeling via increasing the expression of metastatic factors (such as VEGF-A, WNT5A, TGFβ1, and periostin) and generating a favoring-growth tumor environment [67].